Indication

Hypothalamic obesity

Hypothalamic obesity is a severe neuroendocrine disorder characterized by rapid, intractable weight gain resulting from structural or functional damage to the hypothalamic nuclei that control energy homeostasis. Read more about Hypothalamic obesity

1 drugs 1 manufacturers

Drugs that treat it

Common Hypothalamic obesity therapies.

Showing 1–1 of 1 drugs

Sort

IMCIVREE (setmelanotide acetate)

DIET AIDS·OBESITY DUE TO PROOPIOMELANOCORTIN (POMC) DEFICIENCY·+4

RHYTHM PHARMACE

Filter & compare in the drug finder →Opens the drug finder with Hypothalamic obesity preselected.

News & literature

Coming soon

Related codes

Coming soon

About Hypothalamic obesity.

It predominantly arises in pediatric and adult populations following sellar or suprasellar tumors—most frequently craniopharyngiomas—as well as subsequent neurosurgical resections, cranial radiotherapy, or traumatic brain injury.

Pathophysiologically, the condition is driven by impaired central satiety signaling, reduced sympathetic tone, disrupted leptin and insulin signaling, and vagally mediated hyperinsulinemia.

Clinically, affected individuals exhibit profound hyperphagia paired with markedly decreased resting energy expenditure, producing excessive adiposity that is characteristically refractory to standard lifestyle and behavioral interventions.

nih.gov
Hypothalamic obesity is a severe neuroendocrine disorder characterized by rapid, intractable weight gain resulting from structural or functional damage to the hypothalamic nuclei that control energy homeostasis It predominantly arises in pediatric and adult populations following sellar or suprasellar tumors—most frequently craniopharyngiomas—as well as subsequent neurosurgical resections, cranial radiotherapy, or traumatic brain injury Pathophysiologically, the condition is driven by impaired ce...
nih.gov
Hypothalamic obesity is a severe neuroendocrine disorder characterized by rapid, intractable weight gain resulting from structural or functional damage to the hypothalamic nuclei that control energy homeostasis Clinically, affected individuals exhibit profound hyperphagia paired with markedly decreased resting energy expenditure, producing excessive adiposity that is characteristically refractory to standard lifestyle and behavioral interventions
nih.gov
It predominantly arises in pediatric and adult populations following sellar or suprasellar tumors—most frequently craniopharyngiomas—as well as subsequent neurosurgical resections, cranial radiotherapy, or traumatic brain injury Clinically, affected individuals exhibit profound hyperphagia paired with markedly decreased resting energy expenditure, producing excessive adiposity that is characteristically refractory to standard lifestyle and behavioral interventions
nih.gov
It predominantly arises in pediatric and adult populations following sellar or suprasellar tumors—most frequently craniopharyngiomas—as well as subsequent neurosurgical resections, cranial radiotherapy, or traumatic brain injury
nih.gov
Pathophysiologically, the condition is driven by impaired central satiety signaling, reduced sympathetic tone, disrupted leptin and insulin signaling, and vagally mediated hyperinsulinemia
nih.gov
Pathophysiologically, the condition is driven by impaired central satiety signaling, reduced sympathetic tone, disrupted leptin and insulin signaling, and vagally mediated hyperinsulinemia

Personalize your experience

Follow Hypothalamic obesity and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it